Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.49 |
| ▸ | MME | P08473 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.46 |
| ▸ | CPA1 | P15085 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.42 |
| ▸ | BHMT | Q93088 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10494263 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL2807590 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL4957790 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL3341838 | 1.00 | LTA4H (0.49) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL31170917 | 0.96 | LTA4H (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30198622 | 0.96 | LTA4H (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30797948 | 0.91 | GNPAT (0.46) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL29374714 | 0.90 | BACE1 (0.48) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30408803 | 0.88 | PTPN1 (0.45) | LTA4HMMEACECPA1ACE2 | |
| SCHEMBL30317542 | 0.88 | BACE1 (0.43) | LTA4HMMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115047120-B | Method for analyzing and detecting dansyl chloride derivative of dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2023-08-29 | — | — | CN | claimed |
| EP-4175982-A1 | NEUTRALIZING ANTIBODIES TO SARS CORONAVIRUS-2 | FONDAZIONE TOSCANA LIFE SCIENCES (IT) | 2023-05-10 | — | — | EP | claimed |
| CN-111875668-B | Synthetic method of cyclic dipeptide containing glutamine or asparagine | 陕西慧康生物科技有限责任公司 | 2022-05-27 | — | — | CN | claimed |
| CN-101237850-A | Pharmaceutical composition containing indomethacin and/or acemetacin | DROSSAPHARM AG (CH) | 2008-08-06 | — | — | CN | claimed |
| US-20250332246-A1 | ENHANCED EXPRESSION VIA AUTOTRANSPORTERS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025222300-A1 | ATRIAL NATRIURETIC PEPTIDE CONSTRUCTS FOR TARGETED PAYLOAD DELIVERY TO NPR-C EXPRESSING CELLS | PROTEINQURE INC. (CA) | 2025-10-30 | — | — | WO | disclosed |
| US-20250241992-A1 | COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES | GILA THERAPEUTICS INC (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250121033-A1 | PEPTIDE YY PHARMACEUTICAL FORMULATIONS, COMPOSITIONS, AND METHODS | GILA THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-114957438-B | Human Abeta 1-42 epitope polypeptide for detecting Alzheimer disease and preparation method thereof | 福建亿彤生物科技有限公司 | 2024-04-02 | — | — | CN | disclosed |
| US-11911445-B2 | Peptide YY pharmaceutical formulations, compositions, and methods | GILA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230303626-A1 | MACROCYCLIC POLYPEPTIDES | UNIVERSITY OF WASHINGTON | 2023-09-28 | — | — | US | disclosed |
| CN-115047120-B | Method for analyzing and detecting dansyl chloride derivative of dipeptide substances in white spirit Daqu | 贵州茅台酒股份有限公司 | 2023-08-29 | — | — | CN | disclosed |
| WO-2008148932-A2 | GLYCOSYLASPARAGINASE FOR TREATMENT OF CANCERS OR INFLAMMATORY DISEASES | OY REAGENA LTD. (FI) | 2008-12-11 | — | — | WO | disclosed |
| CN-101237850-A | Pharmaceutical composition containing indomethacin and/or acemetacin | DROSSAPHARM AG (CH) | 2008-08-06 | — | — | CN | disclosed |
| US-20040197299-A1 | Topically applicable cosmetic/dermatological compositions comprising hydrolase polypeptides having amidase activity and/or products modulating the activity thereof | SOCIETE L'OREAL, S.A. (FR) | 2004-10-07 | — | — | US | disclosed |
| CN-1114368-C | Low solids beverage with improved texture and flavor perception | PROCTER & GAMBLE (US) | 2003-07-16 | — | — | CN | disclosed |
| WO-2002076970-A2 | TOCOPHEROL SUCCINATE DERIVATIVES AND COMPOSITIONS | SONUS PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002076938-A2 | CARBOXYBENZOPYRAN DERIVATIVES AND COMPOSITIONS | SONUS PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| WO-2002076937-A2 | AMINOBENZOPYRAN DERIVATIVES AND COMPOSITIONS | SONUS PHARMACEUTICALS, INC. (US) | 2002-10-03 | — | — | WO | disclosed |
| CN-1292646-A | Low solids beverage with improved texture and flavor perception | PROCTER & GAMBLE (US) | 2001-04-25 | — | — | CN | disclosed |